

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Broad-spectrum Oral Antibacterial Agent
Gracevit[®] tablets 50mg/fine granules 10%
Receives Approval for Manufacturing and Marketing

Tokyo, January 28, 2008 – DAIICHI SANKYO COMPANY, LIMITED (hereafter; DAIICHI SANKYO) announced it received approval on January 25 for its broad-spectrum antibacterial agent Gracevit[®] (generic name: sitafloxacin hydrate) from the Japanese Ministry of Health, Labour and Welfare. Gracevit[®] is to be marketed in 50 mg tablet form and as a 10% fine granular preparation.

DAIICHI SANKYO currently markets Cravit[®], which is in the same class as Gracevit[®], in tablet form and as a fine granular preparation. Cravit[®] is highly acclaimed for its clinical efficacy and safety. However, Gracevit[®] exhibits potent antibacterial activity with a broad spectrum and DAIICHI SANKYO expects it to be clinically effective in severe cases of bacterial infection, relapse/recrudescence of infection and infections where resistant bacteria are the suspected cause. The anticipated Gracevit[®] can be prescribed as the new quinolone oral antibacterial agent.

Promoting drug compliance and ensuring safety for Gracevit[®] are top priorities for DAIICHI SANKYO and the company is set to provide information for these purposes. In addition to Cravit[®], DAIICHI SANKYO is confident Gracevit[®] can further contribute to the treatment of infectious diseases.